

**Product Name:** PMX 53  
**CAS Number:** 219639-75-5

**Catalog No.:** 5473      **Batch No.:** 10

**1. PHYSICAL AND CHEMICAL PROPERTIES**

**Batch Molecular Formula:** C<sub>47</sub>H<sub>65</sub>N<sub>11</sub>O<sub>7</sub>  
**Batch Molecular Weight:** 896.1  
**Physical Appearance:** White lyophilised solid  
**Counter Ion:** TFA  
**Solubility:** Soluble to 2 mg/ml in water  
**Storage:** Store at -20°C  
**Peptide Sequence:** Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)

**2. ANALYTICAL DATA**

**HPLC:** Shows 97.6% purity  
**Mass Spectrum:** Consistent with structure

**3. AMINO ACID ANALYSIS DATA**

Amino Acid		Theoretical	Actual	Amino Acid		Theoretical	Actual
Ala				Lys			
Arg	1.00		1.01	Met			
Asx				Phe	1.00		0.98
Cys				Pro	1.00		1.01
Glx				Ser			
Gly				Thr			
His				Trp	1.00		Not Detected
Ile				Tyr			
Leu				Val			

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**Product Name:** PMX 53**Catalog No.:** 5473**Batch No.:** 10

CAS Number: 219639-75-5

**Description:**

PMX 53 is a potent C5a receptor antagonist (IC<sub>50</sub> = 20 nM). Also MrgX2 agonist. Stimulates MrgX2-mediated mast cell degranulation. Also inhibits C5a-induced hypernociception in rats, inhibits lung metastasis in a mouse breast cancer model and reduces atherosclerotic lesions in a mouse model of atherosclerosis. Negative Control also available.

**Physical and Chemical Properties:**Batch Molecular Formula: C<sub>47</sub>H<sub>65</sub>N<sub>11</sub>O<sub>7</sub>

Batch Molecular Weight: 896.1

Physical Appearance: White lyophilised solid

**Peptide Sequence:****Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)****Storage:** Store at -20°C**Solubility & Usage Info:**

Soluble to 2 mg/ml in water

This product is supplied in lyophilized form. It may appear as a solid, gel or film and be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

**Counter Ion:** TFA**Stability and Solubility Advice:**

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Peptides in solution are much less stable than in lyophilized form. This is especially true for peptides whose sequences contain amino acids such as Cys, Met, Trp, Asn, Gln, and N-terminal Glu.

Therefore we recommend storing peptides in solution for as short a time as possible. Avoid repeated freeze thaw cycles by dividing the peptide solution into aliquots and storing the aliquots at -20°C. Any portion of an aliquot unused after thawing should be discarded.

Peptides stored in solution can occasionally be susceptible to bacterial degradation. We recommend using sterile solutions or passing the peptide solution through a 0.2 µm filter to remove potential bacterial contamination whenever possible.

**References:**

**Kumar et al** (2018) Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. *Sci.Rep.* **8** 8101. PMID: 29802264 .

**Vadrevu et al** (2014) Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. *Cancer Res.* **74** 3454. PMID: 24786787.

**Manthey et al** (2011) Complement C5a inhibition reduces atherosclerosis in ApoE<sup>-/-</sup> mice. *FASEB J* **25** 2447. PMID: 21490292.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**

info@bio-techne.com

techsupport@bio-techne.com

**North America**

Tel: (800) 343 7475

**China**

info.cn@bio-techne.com

Tel: +86 (21) 52380373

**Europe Middle East Africa**

Tel: +44 (0)1235 529449

**Rest of World**

www.tocris.com/distributors

Tel:+1 612 379 2956